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GENERAL COMMENTS
The authors want to test metformin in patients with diabetes after transplantation: a reasonable goal in this setting! Since patients were not thoroughly evaluated pre-transplant, the term NODAT should be changed to PTDM (post-transplant diabetes mellitus, see: Sharif A et al. Am J Transplant 2014) . Similarly, ref. 15 is completely outdated and should be replaced by the respective reference. The study will be a single-centre, unblinded, pilot randomised controlled trial Metformin has been shown to be safe in large registry data, obviously the number of MALA is too low: hence it is nearly impossible to assess safety in a rather small population like this. Feasibility of recruitment is sensitive as primary endpoint. The GSRS is an accurate method for tolerability. Ad efficacy of metformin: why only morning blood glucose and not OGGT comparing between groups or baseline to 12 months? Overall: where is the power analysis? Why do the authors not increase the dose of metformin? Is there a regular lactate measurement at specific timepoints also in the absence of any clinical symptoms, and if so an analysis of metformin levels when lactate is profoundly increased to rule in/out MALA? Regarding exclusion criteria: 3. "Steroid pulse therapy (IV or oral) in 2 weeks prior to OGTT" This seems to be too short and overall confounded by high dose steroid therapy, hence I would suggest at least 8-12 weeks after the pulse therapy. Are the patients specifically informed to stop metformin intake in case of acute illness such as fever, diarrhea, etc.?
VERSION 1 -AUTHOR RESPONSE
Response to the reviewers:
Comments of reviewer 1: 1. We suggest that lactate levels should be included in the protocol
Response:
The clinical utility of systematic monitoring of lactate levels in asymptomatic patients is questionable especially with large, high quality data showing very low rates of MALA even in patients with moderately impaired eGFR. However, given that safety is one of the primary outcomes of this pilot study, we feel that it is reasonable to incorporate lactate levels in the protocol where it is clinically indicated (i.e. significant GI side effects, major change in eGFR, acute illness, etc). Lactate levels in this context can serve as a helpful tool to aid physicians' decision to alter or stop metfromin therapy.
Minor comments
2. 50% incidence of NODAT is rather highResponse:
We appreciate the reviewer's comment regarding the high risk at the upper end of the spectrum quoted. However, few epidemiological studies and review papers reported such high incidence with wide range of risk. This is largely due to the heterogeneity involved in the field of renal transplantation.
Many experienced centres are transplanting older and more comorbid recipients in recent years. In addition, there are considerable differences in the immunosuppression practices with some centers having steroids free maintenance approach, especially in the immunologically low risk patients. Furthermore, the lack of a uniform approach to diagnose PTDM leads to variable results with some tests underestimating the true incidence, i.e. one-point blood sugar levels (fasting or random). Because of these factors among others we feel that this wide range is probably reflective of the current incidence worldwide. References:
• Sharif A, Cohney S, Post-transplantation diabetes-state of the art. Lancet Diabetes Endocrinology. 2016 Apr;4(4):337-49.
• Palepu S, Prasad GV, New onset diabetes mellitus after kidney transplantation : Current status and future directions. World J Diabetes. We agree with the reviewer's recommendations and we amended the content of our paper accordingly.
2. Metformin has been shown to be safe in large registry data, obviously the number of MALA is too low: hence it is nearly impossible to assess safety in a rather small population like this.
Response:
We agree that the risk is of MALA is very low. However, most of the available data is derived from non-transplant patients. The renal transplant cohort is inherently different with frequent fluctuation of renal function. This can happen in the context of transplant related complications (i.e wound infections, obstruction, urinary leak, etc), immunosuppressants' side effects (i.e vomiting and diarrhoea with mycophenolate, nephrotoxicity with calcineurin inhibitors, etc), and opportunistic infections. Although we agree that no major statements should be derived in regards to MALA in renal transplant patients based on this pilot study, it would still be helpful to assess safety systematically before designing larger RCTs.
3. Ad efficacy of metformin: why only morning blood glucose and not OGGT comparing between groups or baseline to 12 months?
Response: This is a reasonable suggestion, however, we are mindful of the practicality of requesting OGGTs on multiple time points in non-central locations where most of these patients will be followed up after the first month. This will require the patients to find laboratories that can accommodate the test and arrange it with them in advance with minimal flexibility in timing due to the nature of OGTT. Also the patients will have to agree to stay in the laboratories for at least 2 hours between the blood tests added to their normal waiting times. However, we still had OGTT as a secondary end point at enrolment and at 12 months, which we believe will be more manageable by the patients and will help their adherence to the protocol.
4. Overall: where is the power analysis?
Response:
We considered providing power analysis to suggest how many patients will be needed for an efficacy trial in the future, which is very likely to require collaboration between many centres and even countries to recruit the needed number of patients. However, if we are to provide such analysis now it will be completely based on data on incidence, prevention and dosages of metformin in nontransplant patients. For example, metformin reduced the chance of progression to diabetes in at risk group by 31% over 3 years compared with placebo, providing a number needed to treat (NNR) of 13.9 to prevent one case of diabetes (1). Therefore, for a dichotomus outcome when enrolling at 1:1 ratio (p value <0.05 and 80% power), 1142 patients will be needed. Also, a meta-analysis looking at a number of papers suggested comparable benefit with 40% reduction in the metformin group in 1.8 years and an NNR of 17 (2). Therefore, we are contemplating to provide the power analysis upon completion of our study and to publish that with the support of our findings to aid a more informative planning for larger RCTs in these patients. We didn't set an upper target dose of metformin as we felt that this decision is dependant on multiple clinical factors that should be taken into account such as, level of fasting blood glucose/HbA1c, change in kidney function, GI symptoms (related to metformin or to another medication, i.e mycophenolate). We allow the caring physician to increase the dose of metformin on his/her discretion and to record the reason for any dose change.
6. Is there a regular lactate measurement at specific timepoints also in the absence of any clinical symptoms, and if so an analysis of metformin levels when lactate is profoundly increased to rule in/out MALA? Response: We refer to the response for the comment number 1 by the first reviewer 7. "Steroid pulse therapy (IV or oral) in 2 weeks prior to OGTT" This seems to be too short and overall confounded by high dose steroid therapy, hence I would suggest at least 8-12 weeks after the pulse therapy.
We agree with the reviewer that high dose steroid therapy can confound the OGTT if done too soon. However, the exact duration that should be allowed between the exposure and testing is not entirely clear especially in transplant patients. These patients have other time-dependant risk factors for impaired glucose metabolism after transplantation that need to be taken into account. It has been well documented that rates of impaired glucose metabolism in recipients of renal transplantation increase steadily in the first year post transplantation even in the absence of steroids pulse therapy. This is likely multifactorial as discussed in our paper (weight gain, relaxed dietary restrictions, universal CNI therapy and ongoing steroids exposure). The more time to lapse after the transplantation the more likely for these factors to have deleterious effects on glucose metabolism. Overall, impaired glucose metabolism beyond 2 weeks after the steroids pulse therapy is likely to confer a risk in this cohort of patients. Therefore, we feel that assessing the metformin therapy in these patients is within the scope of this pilot study.
8. Are the patients specifically informed to stop metformin intake in case of acute illness such as fever, diarrhea, etc.? Response:
The patients are educated during the consent/enrollment process of all the possible side effects of metformin, these are also included in the study's information sheet provided to the patients. They are asked to report to the caring physician if any of these symptoms occur. Also, the physicians involved in the care of the recruited patients are informed of the patients' enrollment in the study and provided with the study protocol upon the transfer of their care. 
GENERAL COMMENTS
Interesting and relevant
